Elizabeth E. Tallett
Known title: DirectorCIK: 0001192460
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Elevance Health Q3 Outlook: Premium Pressures and Sector Peer Trends. Elevance Health is preparing for its third-quarter earnings report, with analysts examining key metrics and the potential impact of lower premiums on the company's results. Broader sector news highlights peers like UnitedHealth, Centene, and Oscar Health pursuing growth and cost-saving strategies amidst shifting premium dynamics. The market is observing how these competitive and industry-wide pressures will align with Elevance Health's upcoming performance.
Transaction History
| MRNA | ▲ Buy | Option Exercise | 4,058 | — | 4/30/2026 | View on chart |
| ELV | ▲ Buy | Grant | 388 | $0 | 5/15/2024 | View on chart |
| ELV | ▲ Buy | Grant | 457 | $0 | 5/10/2023 | View on chart |
| ELV | ▲ Buy | Grant | 440 | $0 | 5/18/2022 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 703 | $0 | 4/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MRNA hits 52-week high after Goldman raises target
The stock reached a new 52‑week high after Goldman Sachs increased its price target, citing upcoming melanoma data. This move aligns with a broader rotation of capital into healthcare names, lifting Moderna by about 6% and pushing the share price near the top of its 52‑week range. Analyst coverage shows an average target of $122.67, while recent commentary highlights interest in cancer vaccine developments.
MRNA hits 52-week high after Goldman raises target. The stock reached a new 52‑week high after Goldman Sachs increased its price target, citing upcoming melanoma data. This move aligns with a broader rotation of capital into healthcare names, lifting Moderna by about 6% and pushing the share price near the top of its 52‑week range. Analyst coverage shows an average target of $122.67, while recent commentary highlights interest in cancer vaccine developments.